Brief: Lucid Diagnostics Receives Notice Of Allowance For Key Patent Underlying Its Esoguard Esophageal DNA Test
15/10/2024 13:06
Oct 15 (Reuters) - Lucid Diagnostics Inc LUCD.O :
* LUCID DIAGNOSTICS RECEIVES NOTICE OF ALLOWANCE FOR KEY
PATENT
UNDERLYING ITS ESOGUARD ESOPHAGEAL DNA TEST
Source text for Eikon: ID:nPn3vgZZPa
Further company coverage: LUCD.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Lucid Diagnostics
See all newsLucid Diagnostics Inc reports results for the quarter ended June 30 - Earnings Summary
Lucid Diagnostics Inc expected to post a loss of 7 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE- Lululemon, United Rentals, cannabis stocks
U.S. STOCKS ON THE MOVE- American Airlines, Pot stocks, Paramount Skydance
Lucid Diagnostics falls on $18 mln direct stock deal